

Exondys 51™ (eteplirsen) (Intravenous)

Document Number: IC-0284

Last Review Date: 08/01/2022

Date of Origin: 11/22/2016

Dates Reviewed: 11/2016, 10/2017, 08/2018, 10/2018, 08/2019, 02/2020, 08/2020, 08/2021, 08/2022

I. Length of Authorization

Coverage will be for 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Exondys 51 100 mg/2 mL single-dose vial: 4 vials per 7 days
- Exondys 51 500 mg/10 mL single-dose vial: 7 vials per 7 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- 350 billable units (3500 mg) every 7 days

III. Initial Approval Criteria

Coverage is provided in the following conditions:

Universal Criteria

- Patient is not on concomitant therapy with other DMD-directed antisense oligonucleotides (e.g., golodirsen, casimersen, viltolarsen, etc.); **AND**

Duchenne Muscular Dystrophy (DMD) † Φ 1-12

- Patient has a confirmed mutation of the *DMD* gene that is amenable to exon 51 skipping; **AND**
- Patient has been on a stable dose of corticosteroids, unless contraindicated or intolerance, for at least 6 months; **AND**
- Patient retains meaningful voluntary motor function (e.g., patient is able to speak, manipulate objects using upper extremities, ambulate, etc.); **AND**
- Patient is receiving physical and/or occupational therapy; **AND**
- Baseline documentation of one or more of the following:
 - Dystrophin level
 - Timed function tests (e.g., 6-minute walk test [6MWT], time to stand [TTSTAND], time to run/walk 10 meters [TTRW], time to climb 4 stairs [TTCLIMB], etc.)
 - Upper limb function (ULM) test
 - North Star Ambulatory Assessment (NSAA) score

- Forced Vital Capacity (FVC) percent predicted

† FDA-labeled indication(s); ‡ Compendia recommended indication(s); Ⓞ Orphan Drug

IV. Renewal Criteria ¹⁻¹²

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hypersensitivity reactions (e.g., bronchospasm, chest pain, cough, tachycardia, urticaria, etc.), etc.; **AND**
- Patient has responded to therapy compared to pretreatment baseline in one or more of the following (not all-inclusive):
 - Increase in dystrophin level
 - Improvement in quality of life
 - Stability, improvement, or slowed rate of decline in one of the following:
 - Timed function tests (e.g., 6-minute walk test [6MWT], time to stand [TTSTAND], time to run/walk 10 meters [TTRW], time to climb 4 stairs [TTCLIMB], etc.)
 - Upper limb function (ULM) test
 - North Star Ambulatory Assessment (NSAA) score
 - Forced Vital Capacity (FVC) percent predicted

V. Dosage/Administration ¹

Indication	Dose
Duchenne Muscular Dystrophy	Administer 30 mg/kg intravenously once weekly

VI. Billing Code/Availability Information

HCPCS Code:

- J1428 – Injection, eteplirsen, 10 mg; 1 billable unit = 10 mg

NDC(s):

- 100 mg/2 mL single-dose vial: 60923-0363-xx
- 500 mg/10 mL single-dose vial: 60923-0284-xx

VII. References

1. Exondys 51 [package insert]. Cambridge, MA; Sarepta Therapeutics, Inc.; January 2022. Accessed June 2022.
2. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Ann Neurol*. 2013 Nov;74(5):637-47. doi: 10.1002/ana.23982.
3. Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Ann Neurol*. 2016 Feb;79(2):257-71. doi: 10.1002/ana.24555.
4. Alfano LN, Charleston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. *Medicine (Baltimore)*. 2019 Jun;98(26):e15858. doi: 10.1097/MD.00000000000015858.
5. Topaloglu H, Gloss D, Moxley RT 3rd, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016 Jul 12;87(2):238.
6. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*; 2010 Jan; 9(1):77-93.
7. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol*; 2010 Jan; 9(2):177-189.
8. Kinane TB, Mayer OH, Duda PW, et al. Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History. *Journal of Neuromuscular Diseases* 5 (2018) 47–58.
9. Institute for Clinical and Economic Review. Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value. Final Evidence Report. August 15, 2019 https://icer-review.org/wp-content/uploads/2018/12/ICER_DMD-Final-Report_081519-1.pdf. Accessed June 2022.
10. Khan N, Eliopoulos H, et al on behalf of the Eteplirsen Investigators and the CINRG DNHS Investigators. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy. *J. Neuromuscular Dis*, vol. 6, no. 2, pp. 213-225, 2019.
11. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol* 2018; 17:251.
12. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol* 2018; 17:347.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
G71.01	Duchenne or Becker muscular dystrophy

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC